Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Prof. Arun Sanyal
Sign in to receive more information about videos like this
Prof Sanyal describes the histological spectrum from NAFL to NASH and explains the regulatory pathway for the approval for therapies in the field of NASH. It includes selecting the right target, the right population, the right safety and the right efficacy.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.